Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The mild cognitive impairment (MCI) market was valued at USD 2.26 Billion in 2025 and is expected to grow at a CAGR of 5.30%, reaching USD 3.79 Billion by 2035. The market growth is driven by the aging population and rising awareness of early-stage cognitive disorders.
Q1 2026 Market Updates
Geopolitical Impact of Iran, US, and Israel War on the Mild Cognitive Impairment (MCI) Market
United States: The Mild Cognitive Impairment (MCI) Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. IDC revised U.S. IT spending growth from 12.4% to 11.4% for 2026, with similar revisions across other markets as corporate CFOs apply caution in an inflationary, uncertain macroeconomic environment. Microsoft Azure and AWS reported investigating latency spikes at Middle Eastern data center nodes following missile strikes on Dubai and Doha infrastructure. Semiconductor and electronics supply chains routed through the Gulf region are experiencing disruption, with some production inputs stranded aboard ships unable to transit the Strait of Hormuz. IDC revised U.S. IT spending growth from 12.4% to 11.4% for 2026, reflecting corporate caution in an inflationary environment. Despite overall caution, AI-driven infrastructure investment continues to provide structural demand support. Despite spending caution, AI infrastructure investment continues to grow, with the current crisis reinforcing the case for advanced technology adoption to offset rising labor and materials costs.
Iran: Iran's domestic Mild Cognitive Impairment (MCI) sector has been effectively suspended by the conflict. US-Israeli strikes on industrial and civilian infrastructure across Tehran, Mashhad, Isfahan, and other major cities have disrupted all commercial activity. Power outages from attacks on electricity generation facilities have halted manufacturing operations, and the collapse of the commercial banking and logistics system has eliminated any residual trade flows. The broader humanitarian crisis, with over 1,900 casualties and 4,000+ civilian buildings damaged, has redirected the entire Iranian economy toward survival rather than production or consumption.
Israel: Israel's technology sector, a globally significant innovation hub for cybersecurity, semiconductors, AI, and various specialized verticals, is experiencing operational disruption as engineering teams are reduced by military reservist call-ups. Several Israeli companies supply components, software, and services to global Mild Cognitive Impairment (MCI) market participants. Business development activities have been suspended, and some operational timelines extended. However, Israel's proven resilience through previous conflict periods, and the continued operation of critical R&D programmes, suggests the disruption will be temporary rather than structural.
Key Takeaways
Government
- Relevant technology procurement agencies should assess exposure to Gulf-region cloud and semiconductor supply chains, ensuring critical government IT systems have geographic redundancy and are not dependent on disrupted Middle Eastern infrastructure.
- Policymakers should consider technology investment incentives to offset IDC's revised 11.4% U.S. IT spending growth forecast, preventing conflict-driven corporate caution from permanently deferring productive technology capital investment.
- Cybersecurity agencies should elevate threat assessment for government and critical infrastructure systems, as the Iran conflict has been accompanied by extensive cyber operations targeting energy, financial, and communication infrastructure.
Market
- IDC's downward revision of IT spending growth from 12.4% to 11.4% reflects genuine corporate caution, but the structural AI-driven investment cycle remains intact, with the conflict actually creating additional demand for automation, supply chain visibility, and remote operation technology.
- Microsoft Azure and AWS reports of latency spikes at Middle Eastern data center nodes are accelerating enterprise multi-region architecture adoption and geographic redundancy investments that strengthen Ethernet and cloud infrastructure demand.
- The mild cognitive impairment (mci) market benefits from the conflict as a demand catalyst in customer-facing applications, as businesses managing supply chain complexity, customer inquiry volumes, and remote operations require scalable technology platforms at unprecedented scale.
Procurement
- Enterprise technology procurement teams should assess Gulf-region cloud infrastructure exposure and request vendor confirmation that critical SaaS and IaaS services have adequate geographic redundancy outside the conflict zone.
- IT procurement managers should advance planned technology deployments from discretionary to priority status where the platform addresses supply chain visibility, remote operations, or customer communication challenges created by the conflict.
- Technology buyers should review semiconductor and electronics supply chains for Gulf-adjacent manufacturing exposure, building buffer inventory for critical components that may face supply disruption.
2025
Base Year
2019-2025
Historical Period
2026-2035
Forecast Period
-
The market value is highly influenced by the growing geriatric population and technical advancements to offer improved products.
-
The approval and launch of new therapies like Kisunla and LEQEMBI are contributing to the increased availability of new therapies, driving market growth.
-
One of the major market trends includes the introduction of advanced treatments in emerging markets and their cost-effective approaches are expanding access to care.
Compound Annual Growth Rate
5.3%
Value in USD Billion
2026-2035
*this image is indicative*
Mild Cognitive Impairment (MCI) Market Overview
Mild cognitive impairment (CMI) is a neurological disorder in which a patient suffers from poor memory. It is considered a milder initial stage of Alzheimer's disease in which cognitive abilities gradually decline. In this condition, memory problems could be mild and hardly noticeable to individuals, and writing reminders and taking notes may allow a person to compensate for memory difficulties.
Mild Cognitive Impairment (MCI) Market Growth Drivers
FDA Approvals Contributing to Increased Treatment Options and Cost Efficiency
The market is experiencing significant advancements in treatment options, driven by increasing research and approvals. Mild cognitive impairment requires innovative therapies, creating a gap in effective treatment options. However, ongoing developments are expected to fill this gap. For instance, in July 2024, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion). It is intended for adult patients with early symptomatic Alzheimer's disease (AD). It includes individuals with mild cognitive impairment (MCI) as well as those in the early dementia stage of Alzheimer's disease, with confirmed amyloid pathology. Kisunla, administered once a month, is the first and only amyloid plaque-targeting therapy that provides evidence supporting the discontinuation of treatment once amyloid plaques have been cleared. The approval is poised to expand treatment possibilities and drive market growth by offering a novel, cost-effective therapy.
Rising Availability of Treatments to Meet Increasing Mild Cognitive Impairment (MCI) Market Demand
The launch of new treatments in emerging markets is a significant factor driving market growth. For instance, in June 2024, Eisai Co., Ltd. and Biogen Inc., announced that the humanised anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” has been launched in China. LEQEMBI received approval in January 2024 as a treatment for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia. China is the third country to launch LEQEMBI following the United States and Japan. The expansion of LEQEMBI to China is expected to fill the unmet need for effective MCI therapies in a rapidly ageing population, driving market growth.
Mild Cognitive Impairment (MCI) Market Trends
The market is witnessing several trends and developments to improve the global current scenario. Some of the notable trends are as follows:
Mild Cognitive Impairment (MCI) Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Amnestic MCI
- Non-Amnestic MCI
Market Breakup by Treatment Type
- Drugs
- Cholinesterase Inhibitors
- Benzodiazepines
- Antihistamines
- Others
- Therapy
- Cognitive Stimulation Therapy
- Cognitive Behavioral Therapy
- Others
Market Breakup by Indication
- Lewy Body Dementia
- Parkinson’s Disease Dementia
- Alzheimer’s Disease
- Vascular Dementia
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by Age Group
- Children
- Adults
- Geriatric
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Mild Cognitive Impairment (MCI) Market Share
Amnestic MCI Leads the Market Share by Type
Based on type, the Amnestic MCI segment dominates the market share due to its association with memory loss, a primary concern for many patients and healthcare providers. This form of MCI is more commonly identified and treated, leading to higher demand for diagnostic tools and therapies. The prevalence of memory-related symptoms makes Amnestic MCI a focal point in both research and clinical practice.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Mild Cognitive Impairment (MCI) Market Analysis by Region
The United States leads the market due to the rising incidence of geriatric population. The risk of cognitive decline is rising due to the growing ageing population as older individuals are more susceptible to the condition. The presence of a robust healthcare infrastructure and system that is well-funded by the governments and key players stimulates market growth. Heavy investments in research and development activities to explore potent drug candidates, and effective treatment modalities to treat neurodegenerative disease collectively boost market development, augmenting the leading position of the regional market. The availability of top-notch healthcare technologies in the region facilitates the integration of advanced diagnostic tools like AI-based cognitive tests, wearable devices, and neuroimaging technologies.
Additionally, the existence of a highly supportive regulatory environment, with agencies like the United States FDA and their accelerating approval processes for new drugs and therapies targeting the condition, propels regional market growth. Increasing awareness among people about the condition and health initiatives focused on early detection of cognitive decline further bolster the market.
Leading Players in the Mild Cognitive Impairment (MCI) Market
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Inc.
Pfizer Inc., a leading research-based pharmaceutical and biomedical company, is involved in research and development activities to create drugs for cardiovascular diseases. Pfizer plays an important role in neurological research, focusing on Alzheimer’s and mild cognitive impairment.
F.Hoffman-La Roche Ltd
Also known as Roche, it is a Swiss healthcare company focused on developing pharmaceuticals and diagnostics for the healthcare domain across the globe. The company is actively involved in neurological research, developing treatments for Alzheimer’s and other cognitive impairments, holding a dominant position in the market.
Novartis Pharmaceuticals Corporation
Based in Switzerland, the company is a global leader in pharmaceuticals and biotechnology. It focuses on innovative therapies across multiple health areas, including neurology, and is highly active in the treatment development of neurodegenerative diseases.
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals was founded in 1978. It is a multinational company specialising in generic and branded pharmaceuticals. The company focuses on generics and has a growing interest in neurological and cognitive health treatments.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Eisai Co., Ltd., Sun Pharmaceuticals, Teva Pharmaceuticals, and AstraZeneca.
Key Questions Answered in the Mild Cognitive Impairment (MCI) Market
- What was the mild cognitive impairment (MCI) market value in 2025?
- What is the mild cognitive impairment (MCI) market forecast outlook for 2026-2035?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on treatment type?
- How is the market segmented based on the indication?
- What is market segmentation based on type?
- How does segmentation by route of administration influence market dynamics?
- What are the key market segments based on age group?
- Who are the end-users in the market?
- What are the major factors aiding the mild cognitive impairment (MCI) market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major mild cognitive impairment (MCI) market trends?
- Which type is expected to dominate the market?
- Which age group will lead the market segment?
- Which treatment type will dominate the market share?
- Which route of administration will lead the market segment?
- Which end-user will lead the market?
- Who are the key players involved in the mild cognitive impairment (MCI) market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$3299 $2969
-
$5499 $4949
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment Type |
|
| Breakup by Indication |
|
| Breakup by Route of Administration |
|
| Breakup by Age Group |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share